Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
Elutia reported Q1 2026 revenue of $3.1 million, a 6% year-over-year increase, with GAAP gross margin expanding to 57.9% from 46.8% a year earlier. The company highlighted progress on its NXT-41 510(k) submission, with FDA clearance anticipated in Q4 2026, and NXT-41x clearance expected in H1 2027. New automated manufacturing processes are online, supporting a gross margin target of over 80% at scale. Elutia ended the quarter with $28.5 million in cash and $8.0 million in escrow, totaling $36.5 million in liquidity.
Key figures
- Revenue
- 3114000
- Revenue Yoy
- 6%
- Cash on hand
- 28500000
- Escrow funds
- 8000000
- Cash and escrow
- 36500000
- Gross margin gaap
- 57.9%
- Prefunded warrants
- 3200000
- Shares outstanding
- 44200000
- Target market size
- 1500000000
- Adjusted gross margin
- 66.5%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.